Literature DB >> 11173633

The Expression of Lysosomal Proteinases and Their Inhibitors in Breast Cancer: Possible Relationship to Prognosis of the Disease.

Tamara T Lah1, Janko Kos, Andrej Blejec, Snezana Frkovic-Georgio, Rastko Golouh.   

Abstract

Proteolytic enzymes have been proposed as new biological prognostic indicators to facilitate decisions about treatment of breast cancer patients following surgery. We reported earlier that the activities of cysteine proteinases (CP), cathepsin (Cat) B and cathepsin (Cat) L and the expression of stefin A might be associated with breast tumor progression and prognosis. Here, the protein concentrations of Cats D, B and L and stefin A have been measured in a series of 60 matched pairs of breast tumours and control adjacent tissues, using ELISAs developed in our laboratory. Median tumor concentrations of Cat D (47 pm/mg), Cat B (222 ng/mg) and Cat L (88 ng/mg) were significantly (p<0.0005) increased by 7 fold, 27 fold and 6 fold, respectively. Much greater increases in the activities of Cat B (63 fold) and of Cat L (274 fold) were found, indicating activation of proCat B and proCat L and/or to a decrease in specific endogenous cystatins. However, the 1.6-fold decreased (p<0.0001) levels of inhibition by cystatins could not be entirely responsible for more than 100-fold increased ratio of CP:cystatins activity. Moreover, stefin A was either increased or decreased in tumor samples, resulting in a 1.4-fold median increase in tumors. Comparing the biological parameters with the established histo-pathological prognosticators, we found that the increased protein concentration of Cat B was associated with lymph node involvement (p<0.009) and higher stage (p<0.003), and both Cat B and Cat L activities were more increased in high grade tumours (p<0.05). Survival analysis revealed that stefin A was the most significant prognostic factor for disease-free (p<0.008) and overall survival (p<0.02), followed by increased Cat B activity and protein concentration. Cat L was of borderline significance while Cat D was not significant for prognosis. We conclude that enhanced activation of CP, due partially to an imbalance between cysteine proteinases and inhibitors is linked to the progression of breast cancer. Larger sample size is needed to confirm the prognostic significance of stefin A, Cat B and Cat L.

Entities:  

Year:  1997        PMID: 11173633     DOI: 10.1007/bf02907801

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  39 in total

1.  Stefins and lysosomal cathepsins B, L and D in human breast carcinoma.

Authors:  T T Lah; M Kokalj-Kunovar; B Strukelj; J Pungercar; D Barlic-Maganja; M Drobnic-Kosorok; L Kastelic; J Babnik; R Golouh; V Turk
Journal:  Int J Cancer       Date:  1992-01-02       Impact factor: 7.396

2.  Molecular cloning of mouse epidermal cystatin A and detection of regulated expression in differentiation and tumorigenesis.

Authors:  P Hawley-Nelson; D R Roop; C K Cheng; T M Krieg; S H Yuspa
Journal:  Mol Carcinog       Date:  1988       Impact factor: 4.784

3.  Increased expression of cathepsins L and B and decreased activity of their inhibitors in metastatic, ras-transformed NIH 3T3 cells.

Authors:  A F Chambers; R Colella; D T Denhardt; S M Wilson
Journal:  Mol Carcinog       Date:  1992       Impact factor: 4.784

Review 4.  Cathepsin B, Cathepsin H, and cathepsin L.

Authors:  A J Barrett; H Kirschke
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

5.  Cathepsin D inactivates cysteine proteinase inhibitors, cystatins.

Authors:  B Lenarcic; J Kos; I Dolenc; P Lucovnik; I Krizaj; V Turk
Journal:  Biochem Biophys Res Commun       Date:  1988-07-29       Impact factor: 3.575

6.  Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma.

Authors:  M Budihna; P Strojan; L Smid; J Skrk; I Vrhovec; A Zupevc; Z Rudolf; M Zargi; M Krasovec; B Svetic; N Kopitar-Jerala; J Kos
Journal:  Biol Chem Hoppe Seyler       Date:  1996-06

Review 7.  Alterations and role of human cathepsin D in cancer metastasis.

Authors:  H Rochefort; E Liaudet; M Garcia
Journal:  Enzyme Protein       Date:  1996

8.  Cathepsins D, B, and L in malignant human lung tissue.

Authors:  P Ledakis; W T Tester; N Rosenberg; D Romero-Fischmann; I Daskal; T T Lah
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

9.  Kinetics of the pH-induced inactivation of human cathepsin L.

Authors:  B Turk; I Dolenc; V Turk; J G Bieth
Journal:  Biochemistry       Date:  1993-01-12       Impact factor: 3.162

10.  Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma.

Authors:  T Inoue; T Ishida; K Sugio; K Sugimachi
Journal:  Cancer Res       Date:  1994-12-01       Impact factor: 12.701

View more
  6 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma.

Authors:  B Zsebik; K Symonowicz; Y Saleh; P Ziolkowski; A Bronowicz; G Vereb
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

3.  Cystatin C - a fast and reliable biomarker for glomerular filtration rate in head and neck cancer patients.

Authors:  Edwin Bölke; Gisela Schieren; Stephan Gripp; Gerald Steinbach; Matthias Peiper; Klaus Orth; Christiane Matuschek; Maximilian Pelzer; Guido Lammering; Ruud Houben; Christina Antke; Lars Christian Rump; Rodrigo Mota; Peter Arne Gerber; Patrick Schuler; Thomas K Hoffmann; Ethelyn Rusnak; Derik Hermsen; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2011-02-24       Impact factor: 3.621

4.  Identification of early biomarkers in saliva in genetically engineered mouse model C(3)1-TAg of breast cancer.

Authors:  Isadora Fernandes Gilson Sena; Larissa Lessi Fernandes; Leonardo Lima Lorandi; Thais Viggiani Santana; Luciana Cintra; Ismael Feitosa Lima; Leo Kei Iwai; Jill M Kramer; Alexander Birbrair; Débora Heller
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

5.  Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Authors:  A Elzagheid; T Kuopio; S Pyrhönen; Y Collan
Journal:  Diagn Pathol       Date:  2006-11-08       Impact factor: 2.644

6.  Cysteine proteinase inhibitor cystatin C in squamous cell carcinoma of the head and neck: relation to prognosis.

Authors:  P Strojan; I Oblak; B Svetic; L Smid; J Kos
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.